Form 4: Vaxcyte COO Jim Wassil Executes Stock Option and Sells Shares Under 10b5-1 Plan

Vaxcyte's Chief Operating Officer, Jim Wassil, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On September 3, 2024, Jim Wassil, the Chief Operating Officer of Vaxcyte, Inc. (PCVX), exercised a stock option to acquire 10,000 shares of common stock at a price of $2.42 per share.
• Wassil then sold a total of 8,990 shares of common stock in multiple transactions at prices ranging from $108.0126 to $117.025 per share.
• These sales were executed under a Rule 10b5-1 trading plan adopted on March 1, 2024.
• Additionally, 5,545 shares were surrendered to cover tax withholding obligations related to the vesting of restricted stock units at a price of $110.15.
• Following these transactions, Wassil directly owns 201,958 shares of Vaxcyte common stock and holds options for 52,638 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document simply reports stock transactions by an executive under a pre-existing trading plan. There's no inherent positive or negative implication.

Positives

• The sales were executed under a pre-arranged 10b5-1 trading plan, which can mitigate concerns about insider trading.

Risks

• Executive stock sales can sometimes be perceived negatively by investors, even when conducted under a 10b5-1 plan.

Industry Context

Executive stock transactions are common in publicly traded companies, particularly in the biotech industry. Rule 10b5-1 plans are frequently used to allow insiders to sell shares without raising concerns about trading on non-public information.

Comparison to Industry Standards

• Executive compensation packages in the biotech industry often include stock options and restricted stock units to align management's interests with those of shareholders.
• The use of Rule 10b5-1 trading plans is a standard practice among executives to manage their personal finances while avoiding potential insider trading issues.
• Comparing Wassil's stock ownership and trading activity to those of executives at similar-sized biotech companies (e.g., IGM Biosciences, Arcus Biosciences) could provide further context.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders if they perceive it as a lack of confidence by the COO, although the 10b5-1 plan mitigates this concern.
• The tax obligations covered by surrendering shares impact the company's share count.

Key Dates